A polymer-bioactive agent conjugate comprising: a polymer backbone comprising a plurality of 1,2,3-triazole moieties incorporated in the structure of the polymer chain, and forming part of the polymer backbone; and a plurality of releasable bioactive agents covalently bonded to and pendant from the polymer backbone, wherein the bioactive agent are selected from the group consisting of prostaglandin analogues, β-blockers, and mixtures thereof; wherein the prostaglandin analogues are of formula: where: - - - - - - represents a double or single bond; W and U are selected from the group consisting of where W and U together form oxo (=O), where W and U are each halo, and where W is R 15 and U is hydrogen; R y is an optional substituent selected from the group consisting of oxo and hydroxy; Y is optionally substituted C 4 to C 10 hydrocarbyl or optionally substituted C 4 to C 10 hydrocarbyloxy; and one of R 1, R 9, R 11 and R 15 is linked to the polymer backbone and wherein: R 9, R 11 and R 15 when linked to the polymer backbone are the alcohol residue of an ester or carbonate linking group and R 1 when linked to the polymer backbone forms the acid residue of an ester or anhydride linking group; and R 1 when not linked to the backbone is selected from the group consisting of - OH, -O(C 1-6 alkyl), and -NR a R b where R a and R b are each independently selected from the group consisting of H and C 1-6 alkyl; R 9 and R 11 when not linked to the polymer backbone are each hydroxy or where one of R 9 and R 11 is linked to the backbone, the other is hydroxy; and when R 15 is not linked to the backbone then W is hydroxy and U is hydrogen, or W and U are each fluoro, or W and U together form oxo; and the β-blockers are of formula: wherein: E is a bond or -OCH 2 - (preferably -OCH 2 -); R 2 is linked to the polymer backbone and is the alcohol residue of an ester or carbonate linking group; R 3 and R 4 are each independently selected from the group consisting of H, and linear or branched C 1 -C 4 alkyl optionally substituted by one or more substituents selected from the group consisting of hydroxy, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted amido, optionally substituted cycloalkyl, and optionally substituted aryl; (preferably R 3 is H and R 4 is isopropyl or tert-butyl); and R 5 is an optionally substituted cycloalkyl or aryl moiety including polycyclic moieties. a polymer backbone comprising a plurality of 1,2,3-triazole moieties incorporated in the structure of the polymer chain, and forming part of the polymer backbone; and a plurality of releasable bioactive agents covalently bonded to and pendant from the polymer backbone, wherein the bioactive agent are selected from the group consisting of prostaglandin analogues, β-blockers, and mixtures thereof; - - - - - - represents a double or single bond; W and U are selected from the group consisting of where W and U together form oxo (=O), where W and U are each halo, and where W is R 15 and U is hydrogen; R y is an optional substituent selected from the group consisting of oxo and hydroxy; Y is optionally substituted C 4 to C 10 hydrocarbyl or optionally substituted C 4 to C 10 hydrocarbyloxy; and one of R 1, R 9, R 11 and R 15 is linked to the polymer backbone and wherein: R 9, R 11 and R 15 when linked to the polymer backbone are the alcohol residue of an ester or carbonate linking group and R 1 when linked to the polymer backbone forms the acid residue of an ester or anhydride linking group; and R 1 when not linked to the backbone is selected from the group consisting of - OH, -O(C 1-6 alkyl), and -NR a R b where R a and R b are each independently selected from the group consisting of H and C 1-6 alkyl; R 9 and R 11 when not linked to the polymer backbone are each hydroxy or where one of R 9 and R 11 is linked to the backbone, the other is hydroxy; and when R 15 is not linked to the backbone then W is hydroxy and U is hydrogen, or W and U are each fluoro, or W and U together form oxo; and the β-blockers are of formula: R 9, R 11 and R 15 when linked to the polymer backbone are the alcohol residue of an ester or carbonate linking group and R 1 when linked to the polymer backbone forms the acid residue of an ester or anhydride linking group; and R 1 when not linked to the backbone is selected from the group consisting of - OH, -O(C 1-6 alkyl), and -NR a R b where R a and R b are each independently selected from the group consisting of H and C 1-6 alkyl; R 9 and R 11 when not linked to the polymer backbone are each hydroxy or where one of R 9 and R 11 is linked to the backbone, the other is hydroxy; and when R 15 is not linked to the backbone then W is hydroxy and U is hydrogen, or W and U are each fluoro, or W and U together form oxo; and the β-blockers are of formula: E is a bond or -OCH 2 - (preferably -OCH 2 -); R 2 is linked to the polymer backbone and is the alcohol residue of an ester or carbonate linking group; R 3 and R 4 are each independently selected from the group consisting of H, and linear or branched C 1 -C 4 alkyl optionally substituted by one or more substituents selected from the group consisting of hydroxy, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted amido, optionally substituted cycloalkyl, and optionally substituted aryl; (preferably R 3 is H and R 4 is isopropyl or tert-butyl); and R 5 is an optionally substituted cycloalkyl or aryl moiety including polycyclic moieties.